Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ponte, P; Serrao, V; Viana, I; Vale, E; Joao, A; Cerroni, L.
Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin.
J CUTANEOUS PATHOL. 2011; 38(3): 301-305. Doi: 10.1111/j.1600-0560.2009.01476.x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Cerroni Lorenzo
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: CD30+ cutaneous lymphoproliferative disorders (CLPDs) are usually characterized by a benign clinical course. The prognostic value of cytotoxic markers in these lymphomas has not been evaluated in large series. We describe a case of borderline CD30+ CLPD with cytotoxic phenotype, presenting in a 22-year-old male patient as an ulcer on the forearm. He reported having had similar ulcers on the buttock and thigh that spontaneously regressed over the course of 1 year. The lesion resolved with a single course of clarithromycin; a subsequent lesion, too, responded to clarithromycin, and no recurrences or systemic involvement have been documented in the 9-month follow-up. A conservative approach in the management of CD30+ CLPD is recommended. We believe that the anti-inflammatory and apoptotic effects of clarithromycin on T cells may have hastened the remission process.
Find related publications in this database (using NLM MeSH Indexing): Anti-Inflammatory Agents - therapeutic use; Antigens, CD30 - metabolism; Clarithromycin - therapeutic use; Humans -; Lymphoma, T-Cell, Cutaneous - drug therapy; Male -; Skin Neoplasms - drug therapy; Tumor Markers, Biological - analysis; Young Adult -